Clinical trials: COVID-19 Booster
COVID-19, Vaccines
Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake
This study investigates different ways to elevate intentions to get the COVID-19 booster via text-based reminders, including providing information about the booster and leveraging the consistency principle.
- Trial name
- NCT05586178
- Testing
- Reminder that facilitates action, Consistency framing, Information provision about the uniqueness of the bivalent booster
- Where
- United States
- Volunteers
- 177,720 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
COVID-19
Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older
This is an international multicenter clinical trial, which is planned to be conducted in several research centers in China and Pakistan.
- Trial name
- NCT05683600
- Testing
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001
- Where
- 2 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults
This is an open-label, first-in-human, dose-finding study to evaluate the safety and immunogenicity of a booster vaccination of Prime-2-CoV_Beta in healthy participants.
- Trial name
- NCT05389319
- Testing
- Prime-2-CoV_Beta
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
COVID-19, Sars-CoV-2 Infection
Phase 2b Booster Vaccination (TURKOVAC) Against COVID-19
This study is open-label, two arms, multi-centered, phase 2b clinical trial to determine the efficacy, safety, and immunogenicity of booster vaccination (TURKOVAC) against Covid-19.
- Trial name
- NCT05210179
- Testing
- TURKOVAC-Dollvet, TURKOVAC-Koçak
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)
Aim: To investigate if a subcutaneous (s.c.) booster dose of 90 µg of the naked Akston AKS-452 vaccine (AKS-452X) at >= 3 months post initial vaccination, with any of the four registered vaccines, will boost the antibody titer…
- Trial name
- ACT-BOOSTER (NCT05124483)
- Testing
- AKS-452X
- Where
- Netherlands
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID -19
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults.
- Trial name
- NCT07703475
- Testing
- RVX-sCPD9
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population Aged ≥18 Years as Booster Vaccines
The study is a randomized, double-blind, and positive-controlled Phase III booster study. It will evaluate the immunogenicity and safety of one dose of SCTV01C or SCTV01E as booster compared with either one dose of Sinopharm…
- Trial name
- NCT05323461
- Testing
- SCTV01C, SCTV01E, Sinopharm inactivated COVID-19 vaccine
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine
This is an open-label, single-arm clinical trial designed to evaluate the immunogenicity and safety of a booster dose of an adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine (SpikoGen) produced by CinnaGen Co.
- Trial name
- NCT05285384
- Testing
- SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- Where
- Iran
- Volunteers
- 43 people
- Sponsor
- Cinnagen
COVID 19, Influenza
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with…
- Conditions
- COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus
- Trial name
- CO2I2 (NCT06599658)
- Testing
- Inactivated influenza vaccine (IIV) at baseline, COVID-19 Vaccines at a 3-month interval, Inactivated influenza vaccine at Month 1
- Where
- 3 sites in Canada
- Volunteers
- 660 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
This is a randomized, open-labeled, Phase IIb clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of the booster vaccine of using one or two doses of COVID-19 Vaccine (Vero Cell), Inactivated…
- Trial name
- NCT05411471
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
- Where
- China
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech (Hong Kong) Limited
SARS-CoV2 Infection
Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine
This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein…
- Trial name
- NCT06181292
- Testing
- PHH-1V81, Comirnaty Omicron XBB1.5
- Where
- 10 sites in Spain
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19, Sars-CoV-2 Infection
Booster Vaccination Against COVID-19
A booster dose of vaccine (Turkovac or CoronaVac) will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.
- Trial name
- NCT04979949
- Testing
- CoronaVac, Turkovac
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
COVID-19, SARS-CoV-2
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
The purpose of this study is to to evaluate the safety and immune response of COVI-VAC given as a single booster dose in healthy adults previously vaccinated against COVID-19 with an authorised mRNA or adenovirus-vectored…
- Trial name
- NCT05233826
- Testing
- COVI-VAC
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
COVID-19, Vaccine Reaction
The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)
While both heterologous (mixing) and homologous (matching) vaccine regimens are now considered standard of care, post-vaccination complications and long-term effects of the different vaccination regimens have not been thoroughly…
- Conditions
- COVID-19, Vaccine Reaction, COVID-19 Pandemic
- Trial name
- BOOSTED (NCT05268185)
- Testing
- Moderna Booster Vaccine, Pfizer Booster Vaccine
- Where
- United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
COVID-19
IH Convidecia as Second Booster Dose Against Breakthrough Infections
This will be a randomized single-blind controlled trial to determine the immunogenicity, efficacy and safety of IH Convidecia (CanSino), as a second booster vaccination against Omicron and other emerging VOCs to prevent…
- Trial name
- NCT05517642
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH), mRNA vaccine BNT162b2 (Pfizer)
- Where
- Malaysia
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
COVID-19
Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above
A total of 1200 people aged 18 years and older who have completed two or three-dose inactivated COVID-19 vaccine for 6-18 months will be recruited in this study.
- Trial name
- NCT05664932
- Testing
- Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, ZF2001
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
SARS CoV 2 Infection, COVID-19
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
The recent rise in infections with the Omicron variant of the SARS-CoV-2 is alarming. Equally disconcerting is the fact that individuals who were previously vaccinated (< 6 months) and have co-morbidities that are considered high…
- Trial name
- NCT05279365
- Testing
- Pfizer/BioNTech (BNT162b2), Moderna
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- DHR Health Institute for Research and Development
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia.
- Conditions
- COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease
- Trial name
- NCT06259578
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital